These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma. Jasiński M; Basak GW; Jedrzejczak WW Front Immunol; 2021; 12():632937. PubMed ID: 33717171 [TBL] [Abstract][Full Text] [Related]
23. Biobehavioral Implications of Chimeric Antigen Receptor T-cell Therapy: Current State and Future Directions. Taylor MR; Steineck A; Lahijani S; Hall AG; Jim HSL; Phelan R; Knight JM Transplant Cell Ther; 2023 Jan; 29(1):19-26. PubMed ID: 36208728 [TBL] [Abstract][Full Text] [Related]
25. How I treat adverse effects of CAR-T cell therapy. Yáñez L; Alarcón A; Sánchez-Escamilla M; Perales MA ESMO Open; 2020 Aug; 4(Suppl 4):e000746. PubMed ID: 32839196 [TBL] [Abstract][Full Text] [Related]
26. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Kotch C; Barrett D; Teachey DT Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357 [No Abstract] [Full Text] [Related]
27. Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. Chakraborty R; Sidana S; Shah GL; Scordo M; Hamilton BK; Majhail NS Biol Blood Marrow Transplant; 2019 May; 25(5):e155-e162. PubMed ID: 30500439 [TBL] [Abstract][Full Text] [Related]
28. Chimeric antigen receptor T-cell therapy for multiple myeloma. Wang Z; Chen C; Wang L; Jia Y; Qin Y Front Immunol; 2022; 13():1050522. PubMed ID: 36618390 [TBL] [Abstract][Full Text] [Related]
29. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. Roex G; Timmers M; Wouters K; Campillo-Davo D; Flumens D; Schroyens W; Chu Y; Berneman ZN; Lion E; Luo F; Anguille S J Hematol Oncol; 2020 Dec; 13(1):164. PubMed ID: 33272302 [TBL] [Abstract][Full Text] [Related]
30. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT. Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380 [TBL] [Abstract][Full Text] [Related]
31. Advanced Practice Nursing and CAR-T Cell Therapy: Opportunities, Challenges and Future Directions. Kisielewski D; Naegele M Semin Oncol Nurs; 2024 Jun; 40(3):151628. PubMed ID: 38594105 [TBL] [Abstract][Full Text] [Related]
32. Neurological Complications of CAR T Cell Therapy. Landry K; Thomas AA Curr Oncol Rep; 2020 Jul; 22(8):83. PubMed ID: 32607727 [TBL] [Abstract][Full Text] [Related]
36. Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment. Nenna A; Carpenito M; Chello C; Nappi P; Annibali O; Vincenzi B; Grigioni F; Chello M; Nappi F Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897819 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic potential of CAR T cell in malignancies: A scoping review. Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519 [TBL] [Abstract][Full Text] [Related]
38. [CAR-T cell therapy - personalized cellular immunotherapy in 2022]. Niebling J; Bethge W; Lengerke C Dtsch Med Wochenschr; 2022 Nov; 147(23):1552-1564. PubMed ID: 36384157 [TBL] [Abstract][Full Text] [Related]
39. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy. Lindo L; Wilkinson LH; Hay KA Front Immunol; 2020; 11():618387. PubMed ID: 33643299 [TBL] [Abstract][Full Text] [Related]
40. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products. Hunter BD; Rogalski M; Jacobson CA Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]